Diabetes mellitus: A hypercoagulable state

Journal of Diabetes and its Complications

Volumn 15, Issue 1, 2001, Pages 44-54

  Carr, Marcus E ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HUNTER HOLMES MCGUIRE VA MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Clotting factors; Endothelium; Fibrinolysis; Platelets

Indexed keywords

ALPHA 2 MACROGLOBULIN; ANTICOAGULANT PROTEIN; ANTITHROMBIN III; BETA THROMBOGLOBULIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; KALLIKREIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTHROMBIN; PROTHROMBIN ACTIVATION FRAGMENT 1; PROTHROMBIN ACTIVATION FRAGMENT 2; THROMBIN ANTITHROMBIN COMPLEX; THROMBOCYTE FACTOR 4; THROMBOMODULIN; THROMBOXANE B2; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; CAUSE OF DEATH; DIABETES MELLITUS; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR ENDOTHELIUM;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 0035093810     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(00)00132-X     Document Type: Article

References (43)

1. Hypercoagulation in diabetes mellitus
2. Haemostatic factors in black and white diabetics
3. Platelet-dependent thrombin generation in patients with diabetes mellitus: effects of glycemic control on coagulability in diabetes
4. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction
5. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the international tissue plasminogen activator/streptokinase mortality trial
6. Vascular reactivity
7. Platelet and coagulation factors in proliferative diabetic retinopathy
8. Nonenzymatic glycosylation reduces the susceptibility of fibrin to degradation by plasmin
9. Type 2 diabetes: one disease, multiple cardiovascular risk factors
10. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus
11. Effect of fibrin structure on plasmin-mediated dissolution digestion of plasma clots
12. Effect of hyperglycosylated fibrinogen on fibrin assembly, structure and dissolution
13. Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria
14. Thrombin-antithrombin III complexes in type II diabetes mellitus
15. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis
16. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage
17. Diabetes, a hypercoagulable state? Hemostatic variables in newly diagnosed type 2 diabetic patients
18. Plasma fibrinopeptide A levels during insulin-induced plasma glucose falls in diabetics
19. Reduced fibrinogen survival in diabetes mellitus: a reversible phenomenon
20. Hematologic alterations of diabetes mellitus
21. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes. Role of oxidant stress and protein tyrosine kinase activation
22. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force
23. Measurement of prethrombotic markers in the assessment of acquired hypercoagulable states
24. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study
25. Glycosylation of human fibrinogen and fibrin in vitro its consequences on the properties of fibrin(ogen)
26. Elevation of factor XIa-alpha 1-antitrypsin complex levels in NIDDM patients with diabetic nephropathy
27. Change of lipoprotein (a) and coagulative or fibrinolytic parameters in diabetic patients with nephropathy
28. Contact phase of blood coagulation in diabetes mellitus
29. Antithrombin III activity and concentration in diabetes mellitus
30. An analysis of outcome following percutaneous transluminal coronary artery angioplasty. An autopsy series
31. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men
32. Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus
33. Plasma beta-thromboglobulin, platelet factor 4, fibrinopeptide A, and other hemostatic functions during improved, short-term glycemic control in diabetes mellitus
34. Risk factors and outcomes for ischemic stroke
35. The hypercoagulable states
36. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids
37. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease
38. Effect of insulin therapy on coagulation and platelet function in type II (non-insulin-dependent) diabetes mellitus
39. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence
40. Decreased protein C levels in patients with insulin-dependent type I diabetes mellitus
41. Electron microscopical studies of vessels in diabetic peripheral neuropathy
42. Fibrinolysis in patients with diabetic nephropathy determined by plasmin-alpha 2 plasmin inhibitor complexes in plasma
43. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy